Johnson & Johnson

JNJ Stock Report Card

Today's performance

B

Performance

Score: 10/100

JNJ returned -12.72% in the last 12 months. Based on the other stocks in its sector with an average return of -6.87%, its performance is below average giving it a grade of 10 of 100.

Forecast

Score: 63/100

23 analysts offer 12-month price forecasts for JNJ. Together, they have an average target of 176.36, the most optimistic forecast put JNJ at 205 within 12-months and the most pessimistic has JNJ at 90.

Sentiment

Score: 71/100

JNJ had a bullish sentiment score of 71.09% across Twitter and StockTwits over the last 12 months. It had an average of 326.36 posts, 12,302.26 comments, and 41,795.98 likes per day.

Technicals

Score: 11/100

JNJ receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

Score: 100/100

A+

JNJ has missed earnings 0 times in the last 20 quarters.

Profit

Score: 68/100

Out of the last 20 quarters, JNJ has had 19 profitable quarters and has increased their profits year over year on 6 of them.

Volatility

Score: 47/100

JNJ has had a lower than average amount of volatility over the last 12 months giving it a grade of 47 of 100.

Dividend

Score: 100/100

A+

JNJ's most recent dividend was $0.90 per share, based on a share price of $154.54. It was a payout ratio of 61.08% compared to their total earnings.

Johnson & Johnson Summary

New York Stock Exchange / JNJ

Healthcare

Drug Manufacturers—General

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products. It also offers STAYFREE and CAREFREE sanitary pads; o.b. tampons; adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. It serves general public, retail outlets, and distributors. The company's Pharmaceutical segment offers products for rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; HIV/AIDS and COVID-19 infectious diseases; mood disorders, neurodegenerative disorders, and schizophrenia; prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; thrombosis, diabetes and macular degeneration; and pulmonary arterial hypertension. This segment serves retailers, wholesalers, distributors, hospitals, and healthcare professionals directly for prescription use. Its MedTech segment provides electrophysiology products to treat cardiovascular diseases; neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. This segment serves wholesalers, hospitals, and retailers. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Power up your portfolio

Build a portfolio of the best stocks

Pluto makes it easy to build investing strategies and automate your portfolio

See how

Checkout Similar Companies

JNJ scored highly on our reportcard. Here are some similar companies and how they performed.

Novo-Nordisk A/S

$NVO Stock Report Card

Pfizer Inc.

$PFE Stock Report Card

Merck & Co., Inc.

$MRK Stock Report Card

ABBVIE INC.

$ABBV Stock Report Card

AstraZeneca PLC

$AZN Stock Report Card

Novartis AG

$NVS Stock Report Card

UNITEDHEALTH GROUP INCORPORATED (Delaware)

$UNH Stock Report Card

Eli Lilly & Co.

$LLY Stock Report Card

View all stock report cards

Los Angeles, CA

Pluto is not a broker-dealer, investment adviser or member of FINRA. Securities offered by Alpaca Securities LLC (“Alpaca Securities”). Alpaca Securities is a member of FINRA and the Securities Investor Protection Corporation.

Alpaca Securities, LLC (“Alpaca Securities”) is not responsible for and is not providing the technology and services you receive from us to access and manage your brokerage account with Alpaca Securities. You firmly agree to hold Alpaca and its affiliates, owners, directors, employees, clearing firm and agents harmless for any loss or damage arising from the use of or unavailability of the technology and services that we are providing.

The content on this website is for informational purposes only. Pluto does not recommend any specific securities or investment strategies. Investing involves risk & investments may lose value, including the loss of principal. Past performance does not guarantee future results. Investors should consider their investment objectives and risks carefully before investing.